GILD.US Weekly Report · 2026-W30
Gilead Sciences declined 3.71% this week, falling from last week’s close of 134.28 to 129.31. Despite institutional sentiment remaining strong (75.9% positive ratings), the latest quarterly EPS surged 54.81% YoY. A notable contradiction emerges: capital flows show significant net outflows while consensus EPS forecasts turn negative, contradicting the company’s robust recent earnings. Key developments include pipeline breakthroughs in Trodelvy+Keytruda combination therapy and a weekly-dose HIV treatment partner with Merck.
Market Performance
During the week of July 20-24, GILD.US closed at 129.31, down 3.71% from the prior week’s close on July 17 (134.28). Weekly high reached 131.653 and low 129.040, representing a volatility span of 2.01%, with close near the low end. Weekly volume was 5.53 million shares with turnover of $7.18 billion. Relative to the 60-day median volume (approximately 6.5-7.0 million shares), this week’s volume contracted modestly, suggesting diminished market participation. The pattern reflects declining volume alongside price weakness, with no sign of significant accumulation.
Valuation and Earnings
GILD currently trades at P/E of 17.42 and P/B of 6.83. By valuation data, the P/B ratio sits at approximately the 18.9th percentile over the past year—significantly undervalued relative to its own history. However, it remains well above the biotech industry median of 1.77, indicating the company maintains substantial premium over its sector peers. This suggests while valuation appears historically cheap, the company’s relative positioning within the industry remains elevated.
The most recent quarter (Q1 2026) showed EPS of $1.61, up 54.81% YoY; revenue of $6.96 billion, up 4.39% YoY; net profit of $2.021 billion, up 53.69% YoY. EPS growth significantly outpaced revenue growth, reflecting improved margins or better cost management. However, consensus forecasts show forward EPS averaging -0.691, presenting a stark contradiction to the recent earnings strength and suggesting markets anticipate structural headwinds or significant cost charges ahead. This discrepancy warrants close attention.
Capital Flows and Institution Sentiment
Capital flows: As of July 24, large-cap institutions recorded net outflows of $22.424 billion, mid-cap funds $10.572 billion outflows, and retail $18.915 billion outflows—total net outflow of $51.91 billion. Institutional selling coupled with retail liquidation signals deteriorating confidence. This contradicts institutional ratings: among 29 rating shops, 16 issue strong buy, 6 buy, 7 hold, and 0 sell, yielding 75.9% positive sentiment. The consensus price target of 157.52 implies 21.81% upside from current levels. Yet ratings carry lag; capital signals may be more forward-looking.
Competitively, GILD ranks 4th among 498 biotech firms in analyst coverage, affirming recognized competitive strength.
Weekly News Highlights
This week’s developments centered on pipeline progress:
Product Breakthroughs: Trodelvy (sacituzumab govitecan) in combination with Merck’s Keytruda received positive CHMP recommendation in first-line PD-(L)1-positive metastatic triple-negative breast cancer, expanding therapeutic potential. Additionally, a weekly-dose oral HIV treatment co-developed with Merck successfully maintained viral suppression in late-stage trials, offering a long-acting alternative for HIV management.
Corporate Actions: The company’s Brazilian ADR underwent a 5-for-1 stock split with adjustment to 1:12 ratio, reflecting shareholder structure optimization.
Analyst Updates: Goldman Sachs maintained its Hold rating on GILD; various institutions adjusted positions.
Key news links:
- CHMP recommends Gilead’s Trodelvy combined with Keytruda for first-line PD-(L)1-positive metastatic triple-negative breast cancer
- Gilead and Merck’s weekly-dose HIV pill successfully maintained viral suppression in late-stage trial
- Gilead and Merck advance potential blockbuster weekly-dose HIV drug
- Gilead releases press release on weekly oral HIV treatment trial results
- Gilead’s Brazilian ADR executes 5-for-1 stock split with adjustment to 1:12 ratio
- Gilead to report Q2 2026 results with webcast after market close
- Gilead Sciences (GILD) receives Hold rating from Goldman Sachs
- Within two years: build or pay 200%—which US pharma stocks will win?
- Gilead Q2 earnings preview: what you need to know
- Top pharma stocks to watch: July 20
Summary
This week presents three key contradictions in GILD’s signals:
-
Valuation vs. Capital: At historically cheap valuations (PB percentile 18.9%), one would expect bargain-hunting, yet capital flows show significant net outflows with institutions actively exiting. This suggests the market questions whether the valuation discount is justified.
-
Earnings vs. Expectations: Recent earnings (Q1 EPS +54.81% YoY) are robust, yet consensus forward EPS turns negative, indicating markets anticipate structural challenges or significant near-term headwinds.
-
Ratings vs. Price Action: With 75.9% of analysts bullish and a 21.8% upside price target, the stock continues declining—a clear disconnect between analyst sentiment and market reality, suggesting analyst ratings lag true market repricing or fundamental shifts.
The pipeline strength (Trodelvy+Keytruda, weekly-dose HIV therapy) offers growth catalysts, yet near-term capital outflows and uncertainty around earnings sustainability demand careful monitoring.